PROTAC ERα Degrader-5

Name: PROTAC ERα Degrader-5
Brand: MedChemExpress
SKU: HY-112100
Rating: 5.0 (1 reviews)

Cat. No.: HY-112100 Purity: 98.96%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

PROTAC ERα Degrader-5 (compound LP2) consists an ADC linker and a PROTAC, whcih can be conjugated to an antibody to form PACs. PROTAC ERα Degrader-5 conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).

For research use only. We do not sell to patients.

PROTAC ERα Degrader-5 Chemical Structure

CAS No. : 2158322-33-7

Size	Price	Stock	Quantity
1 mg	USD 864	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 1900	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 3000	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of PROTAC ERα Degrader-5:

PROTAC ERα Degrader-1 In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Estrogen Receptor/ERR Isoform Specific Products:

View All Isoforms

Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Estrogen receptor-alpha (ERα)^[1]

In Vitro

Treatment of HER2 expressing cells with HER2 antibody containing PAC Anti-HER2(Endox-XIAP) results in a marked decreased Estrogen Receptor-alpha (ERα) levels with an IC₅₀ of 132 ng/mL. The PROTAC-Antibody Conjugate (PAC) molecules comprise an antibody conjugated via a linker (L1) to a PROTAC, wherein the PROTAC comprises an ubiquitin E3 ligase binding group (“E3LB”), a linker (“L2”) and a protein binding group (“PB”). The following sections describe the components that comprise the PAC. To obtain a PAC having potent efficacy and a desirable therapeutic index, the following components are provided. 1. Antibody (Ab): The antibody portion of a PAC can target a cell that expresses an antigen whereby the antigen specific PAC is delivered intracellularly to the target cell, typically through endocytosis While PACs that comprise an antibody directed to an antigen that is not found on the cell surface may result in less specific intracellular delivery of the PROTAC portion into the cell, the PAC may still undergo pinocytosis. 2. Linkers (L1): A“linker” (L1) is a bifunctional or multifunctional moiety that can be used to link one or more PROTAC moieties (D) to an antibody (Ab) to form a PAC. In some embodiments, PACs can be prepared using a L1 having reactive functionalities for covalently attaching to the PROTAC and to the antibody. 3. PROTAC(D) ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

1674.93

Formula

C₉₄H₁₀₇N₁₃O₁₆

CAS No.

2158322-33-7

Appearance

Solid

Color

White to off-white

SMILES

CN(C(COCCOCCNC(C1=CC=C(C(N2[C@@H](C)[C@H](NC([C@H](C)NC)=O)C(N(CC3=C(OC)C=CC4=C3C=CC=C4)C5=C2C=C(C#N)C=C5)=O)=O)C=C1)=O)=O)CCOC(C=C6)=CC=C6/C(C7=CC=C(OCC(C=C8)=CC=C8NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN9C(C=CC9=O)=O)=O)=O)=O)C=C7)=C(C%10=CC=CC=C%10)/CC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : 70 mg/mL (41.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.5970 mL	2.9852 mL	5.9704 mL
5 mM	0.1194 mL	0.5970 mL	1.1941 mL
10 mM	0.0597 mL	0.2985 mL	0.5970 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (1.49 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.75 mg/mL (1.04 mM); Clear solution

This protocol yields a clear solution of ≥ 1.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (17.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.96%

Select Batch:

Data Sheet (272 KB) SDS (252 KB)

COA (248 KB) HNMR (590 KB) LCMS (97 KB)

Handling Instructions (2659 KB)

References

[1]. Thomas Pillow, et al. Protac antibody conjugates and methods of use. WO2017201449A1.

Kinase Assay
^[1]

Syntheses of a PAC:
A. Chemical Synthesis of a PROTAC:
i. Attachment of a Linker (L2) to an E3 Ligase Binding Group (E3LB).
ii. Attachment of a protein binding moiety (PB) to an E3LB via a Linker (L2).
B. Preparation of L1-PROTAC:
iii. Attachment of Linker L1 to PROTAC.
C. Preparation of PAC:
iv. Attachment of Antibody (Ab) to PROTAC via Linker L1^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Thomas Pillow, et al. Protac antibody conjugates and methods of use. WO2017201449A1.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	0.5970 mL	2.9852 mL	5.9704 mL	14.9260 mL
	5 mM	0.1194 mL	0.5970 mL	1.1941 mL	2.9852 mL
	10 mM	0.0597 mL	0.2985 mL	0.5970 mL	1.4926 mL
	15 mM	0.0398 mL	0.1990 mL	0.3980 mL	0.9951 mL
	20 mM	0.0299 mL	0.1493 mL	0.2985 mL	0.7463 mL
	25 mM	0.0239 mL	0.1194 mL	0.2388 mL	0.5970 mL
	30 mM	0.0199 mL	0.0995 mL	0.1990 mL	0.4975 mL
	40 mM	0.0149 mL	0.0746 mL	0.1493 mL	0.3731 mL